BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Bladder cancer

  Tyra Looks to Challenge J&J’s Balversa With Early Data for FGFR3 Blocker in Urothelial Carcinoma

  Bank of America analysts said prior to Thursday’s readout that Tyra Biosciences’ TYRA-300 could rival Johnson & Johnson’s kinase inhibitor Balversa, which has suffered from safety concerns and poor tolerability.

  October 25, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Editorial

  Analysts Rally Around Pfizer CEO Amid Starboard Challenge

  Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.

  October 25, 2024

   · 

  4 min read

   · 

  Greg Slabodkin
• 

  Earnings

  Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales

  The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.

  October 25, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Intellia’s CRISPR Gene Editor Cuts Hereditary Angioedema Attacks by 81% in Phase II Study

  Jefferies analyst Maury Raycroft said in a note to investors that Thursday’s mid-stage readout pointed to the “unprecedented” complete response rate of Intellia’s investigational in vivo gene editing therapy in the disorder.

  October 25, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  CDC Reaffirm RSV Vaccination Guidelines, Declines Expanding Coverage to Younger Adults

  The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for adults aged 75 and older, and in seniors 60 to 74 years who are at risk of severe disease.

  October 25, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• News

  Vesalio Announces Clinical Study Initiative for the Recently Launched pVasc Thrombectomy System and Planned Attendance at TCT, VIVA, and VEITH Meetings

  October 25, 2024

   · 

  2 min read
• News

  Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

  October 25, 2024

   · 

  9 min read
• Business

  LabGenomics USA Completes Acquisition of IMD CLIA Labs

  October 25, 2024

   · 

  1 min read
• FDA

  VANTIS VASCULAR RECEIVES FDA CLEARANCE FOR ITS CROSSFAST™ GUIDE EXTENSION SYSTEM

  October 25, 2024

   · 

  2 min read
• Business

  Aurora Spine Corporation Schedules Conference Call to Update Investors and Discuss Third Quarter Fiscal Year 2024 Financial Results

  October 25, 2024

   · 

  2 min read